Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Acquired by Fisher Asset Management LLC

Fisher Asset Management LLC lifted its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 6.9% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 124,399 shares of the company’s stock after purchasing an additional 8,012 shares during the quarter. Fisher Asset Management LLC’s holdings in Medpace were worth $41,524,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently made changes to their positions in the stock. Renaissance Technologies LLC raised its stake in Medpace by 38.3% in the 2nd quarter. Renaissance Technologies LLC now owns 443,588 shares of the company’s stock worth $182,692,000 after acquiring an additional 122,800 shares during the last quarter. Clearbridge Investments LLC raised its stake in shares of Medpace by 55.1% in the second quarter. Clearbridge Investments LLC now owns 403,892 shares of the company’s stock worth $166,343,000 after purchasing an additional 143,481 shares during the last quarter. Westwind Capital raised its stake in shares of Medpace by 800.1% in the second quarter. Westwind Capital now owns 380,929 shares of the company’s stock worth $156,886,000 after purchasing an additional 338,610 shares during the last quarter. AQR Capital Management LLC lifted its holdings in shares of Medpace by 62.3% during the second quarter. AQR Capital Management LLC now owns 310,650 shares of the company’s stock worth $127,941,000 after purchasing an additional 119,257 shares during the period. Finally, Price T Rowe Associates Inc. MD boosted its position in Medpace by 1.3% in the first quarter. Price T Rowe Associates Inc. MD now owns 256,100 shares of the company’s stock valued at $103,504,000 after buying an additional 3,222 shares during the last quarter. 77.98% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

MEDP has been the subject of a number of recent research reports. UBS Group lowered shares of Medpace from a “buy” rating to a “neutral” rating and reduced their price target for the stock from $420.00 to $350.00 in a research report on Friday, September 27th. Baird R W downgraded shares of Medpace from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 23rd. StockNews.com lowered shares of Medpace from a “buy” rating to a “hold” rating in a report on Friday, September 27th. Truist Financial reduced their price objective on Medpace from $415.00 to $397.00 and set a “hold” rating for the company in a research note on Monday, October 14th. Finally, Robert W. Baird upped their target price on Medpace from $349.00 to $354.00 and gave the stock a “neutral” rating in a research note on Monday. Seven equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $380.56.

Medpace Stock Down 0.8 %

Shares of Medpace stock opened at $335.21 on Wednesday. The firm has a market cap of $10.42 billion, a PE ratio of 29.35, a P/E/G ratio of 1.87 and a beta of 1.37. The business has a 50-day moving average price of $339.37 and a 200 day moving average price of $372.21. Medpace Holdings, Inc. has a twelve month low of $268.80 and a twelve month high of $459.77.

Medpace (NASDAQ:MEDP) last announced its earnings results on Monday, October 21st. The company reported $3.01 earnings per share for the quarter, topping the consensus estimate of $2.77 by $0.24. Medpace had a return on equity of 50.87% and a net margin of 17.66%. The business had revenue of $533.32 million during the quarter, compared to the consensus estimate of $540.99 million. During the same period in the prior year, the company posted $2.22 EPS. The business’s quarterly revenue was up 8.3% on a year-over-year basis. On average, sell-side analysts expect that Medpace Holdings, Inc. will post 11.93 EPS for the current year.

Medpace Company Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.